We are live on
!
Find out more
RMCM
Reynders McVeigh Capital Management Portfolio holdings
AUM
$1.98B
1-Year Est. Return
23.37%
This Fund
S&P 500
This Quarter
Est. Return
+26.41%
1 Year Est. Return
+23.37%
3 Year Est. Return
+85.22%
5 Year Est. Return
+113.19%
10 Year Est. Return
+523.93%
AUM
$1.14B
AUM Growth
+$265M
(+30%)
Cap. Flow
+$51.1M
Cap. Flow
% of AUM
4.47%
Top 10 Holdings %
Top 10 Hldgs %
35.71%
Holding
219
New
26
Increased
98
Reduced
67
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Carrier Global
CARR
|
+$8.44M |
| 2 |
Apple
AAPL
|
+$5.78M |
| 3 |
Walt Disney
DIS
|
+$3.71M |
| 4 |
Microsoft
MSFT
|
+$3.28M |
| 5 |
Sysco
SYY
|
+$3.25M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novartis
NVS
|
+$3.08M |
| 2 |
MarketAxess Holdings
MKTX
|
+$1.95M |
| 3 |
Teladoc Health
TDOC
|
+$1.62M |
| 4 |
Envista
NVST
|
+$1.6M |
| 5 |
IPG Photonics
IPGP
|
+$1.45M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 28.32% |
| 2 | Technology | 20.78% |
| 3 | Industrials | 11.48% |
| 4 | Financials | 11.02% |
| 5 | Communication Services | 10.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Gilead Sciences
GILD
$168B
| $1M | 0.09% |
13,056
+1,459
| +13% | +$112K |
|
102
JPMorgan Chase
JPM
$971B
| $1M | 0.09% |
10,643
-214
| -2% | -$20.3K |
|
103
Ionis Pharmaceuticals
IONS
$9.43B
| $981K | 0.09% |
16,640
-1,750
| -10% | -$97.4K |
|
104
Applied Materials
AMAT
$436B
| $948K | 0.08% |
15,680
+2,108
| +16% | +$114K |
|
105
Emerson Electric
EMR
$91.7B
| $924K | 0.08% |
14,888
-2,400
| -14% | -$136K |
|
106
IBM
IBM
$221B
| $906K | 0.08% |
7,843
-340
| -4% | -$39.5K |
|
107
S&P Global
SPGI
$121B
| $822K | 0.07% |
2,496
+46
| +2% | +$13.8K |
|
108
Arthur J. Gallagher & Co
AJG
$65.3B
| $819K | 0.07% |
+8,404
| New | +$744K |
|
109
Blackrock
BLK
$180B
| $819K | 0.07% |
+1,505
| New | +$760K |
|
110
Mercado Libre
MELI
$93.5B
| $812K | 0.07% |
+824
| New | +$618K |
|
111
Adobe
ADBE
$103B
| $804K | 0.07% |
1,847
+291
| +19% | +$108K |
|
112
Target
TGT
$69.7B
| $804K | 0.07% |
6,706
+1,777
| +36% | +$203K |
|
113
DTE Energy
DTE
$28.7B
| $782K | 0.07% |
8,543
| – | – |
|
114
Kimberly-Clark
KMB
$36.3B
| $782K | 0.07% |
5,535
-142
| -3% | -$19.6K |
|
115
iShares Russell Mid-Cap Growth ETF
IWP
$21B
| $779K | 0.07% |
9,850
| – | – |
|
116
Colgate-Palmolive
CL
$73.8B
| $768K | 0.07% |
10,487
+134
| +1% | +$9.52K |
|
117
Brookfield Renewable
BEP
$10.3B
| $760K | 0.07% |
+29,791
| New | +$748K |
|
118
Medtronic
MDT
$116B
| $750K | 0.07% |
8,174
+2,225
| +37% | +$213K |
|
119
Vanguard Morningstar Small-Cap Growth ETF
VBK
$24.8B
| $705K | 0.06% |
3,530
-300
| -8% | -$54.2K |
|
120
State Street SPDR S&P Dividend ETF
SDY
$22.1B
| $692K | 0.06% |
7,591
| – | – |
|
121
Descartes Systems
DSGX
$6.64B
| $661K | 0.06% |
12,500
+3,540
| +40% | +$157K |
|
122
WisdomTree US LargeCap Dividend Fund
DLN
$6.42B
| $650K | 0.06% |
14,000
| – | – |
|
123
Mettler-Toledo International
MTD
$28.8B
| $648K | 0.06% |
804
-67
| -8% | -$49.8K |
|
124
GSK
GSK
$101B
| $644K | 0.06% |
+12,628
| New | +$648K |
|
125
Boston Scientific
BSX
$74.9B
| $633K | 0.06% |
18,037
-697
| -4% | -$25.1K |
|
Similar funds
SC
CAM
TCM
RCM
LGM
MYAM
NIM
C
Reynders McVeigh Capital Management's Q2 2020 Portfolio in Review
As of Q2 2020, Reynders McVeigh Capital Management held 219 positions worth $1.14B, up 30% from $878M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Reynders McVeigh Capital Management deployed $51.1M of net new capital in Q2 2020, opening 26 new positions and adding to 98 existing holdings. Its largest new stake was Carrier Global: 454,098 shares worth $10.1M.
By sector, the portfolio is most concentrated in Healthcare at 28% of assets, down from 31% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Novartis, an estimated $3.08M trimmed.
- Reynders McVeigh Capital Management's largest Q2 2020 buy was Carrier Global: 454,098 shares worth $10.1M.
- Reynders McVeigh Capital Management added most to Apple in Q2 2020, an estimated $5.78M increase.
- Reynders McVeigh Capital Management's biggest Q2 2020 reduction was Novartis, cutting an estimated $3.08M.
- Reynders McVeigh Capital Management fully exited Chubb in Q2 2020, selling an estimated $1.29M.
- Reynders McVeigh Capital Management's ten largest holdings make up 36% of its $1.14B portfolio in Q2 2020.
- Reynders McVeigh Capital Management opened 26 new positions and closed 10 in Q2 2020.
- Reynders McVeigh Capital Management's portfolio value rose 30% quarter-over-quarter to $1.14B.
Based on Reynders McVeigh Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.